# An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

> **NCT04113616** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

## Interventions

- **DRUG:** KRT-232
- **DRUG:** Cytarabine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT04113616
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-25
- **Primary completion:** 2023-09-27
- **Final completion:** 2023-09-27
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety concerns.
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04113616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04113616, "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04113616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*